Table 2.

Indications for Initiating Therapy in Previously Untreated CLL[18]

▪Evidence of progressive marrow failure: development/worsening anemia or thrombocytopenia ▪Massive (i.e. >6 cm below the left costal margin) or progressive or symptomatic splenomegaly ▪Massive nodes (i.e., >10 cm in longest diameter) or progressive or symptomatic lymphadenopathy ▪Progressive lymphocytosis with an increase of >50% over a 2-month period, or lymphocyte doubling time of less than 6 months ▪Autoimmune anemia and/or thrombocytopenia poorly responsive to corticosteroids or other standard therapy ▪A minimum of any one of the following disease-related symptoms must be present: ◦Unintentional weight loss of >10% within the previous 6 months ◦Significant fatigue (i.e. ECOG performance status 2 or worse) ◦Fevers >100.5°F for 2 or more weeks without evidence of infection ◦Night sweats for >1 month without evidence of infection